1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class and Distribution Channel

Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class and Distribution Channel

  • May 2022
  • 151 pages
  • ID: 6289894
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The chemotherapy-induced peripheral neuropathy market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028.

The report highlights trends prevailing in the market and factors driving the chemotherapy-induced peripheral neuropathy market growth.The market growth is attributed to a rise in demand for cancer drugs and the use of chemotherapy in earlier stages.

However, a lack of awareness regarding the symptoms of chemotherapy-induced peripheral neuropathy limits the market growth.
Peripheral neuropathy is indicated by symptoms that result from damage to the peripheral nerves.These nerves carry sensations, and control arm and leg movements as well as bladder and intestine functions.

Chemotherapy and other medications used to treat cancer can cause peripheral neuropathy, which is termed as chemotherapy-induced peripheral neuropathy.
Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare.Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life.

These therapies may result in the complete remission of a tumor.Owing to these benefits, the demand for chemotherapy has surged globally with the rising burden of cancer.

A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million worldwide from 2018 to 2040.Advanced cancer treatments further improve patient survival and increase the number of patients requiring long-term outpatient chemotherapy.

More exposure to chemotherapy may result in a greater number of CIPN cases, thereby deriving the chemotherapy-induced peripheral neuropathy market growth.
Based on drug class, the chemotherapy-induced peripheral neuropathy market is segmented into steroids, anti-seizure, narcotics, and anti-depressants.In 2021, the steroids segment held the largest share of the market.

However, the anti-seizure segment is expected to register the highest CAGR from 2021 to 2028.Based on distribution channel, the chemotherapy-induced peripheral neuropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment held the largest market share in 2021. However, the retail pharmacies segment is anticipated to register the highest CAGR during the forecast period.
COVID-19 Impact – Chemotherapy-Induced Peripheral Neuropathy Market
The COVID-19 pandemic had a major impact on oncology services at a global level during 2020–2021.It disrupted cancer treatment plans as many healthcare providers had to postpone the diagnosis and treatment of cancer cases.

Moreover, social restrictions and lockdown measures resulted in the discontinuation of clinical trials.. Further, with the rise in COVID-19 burden, healthcare authorities had to conduct reprofiling of many hospitals and departments, including oncology clinics, for treating a large volume of patients. For Instance, in the Netherlands, cancer registry data show a significant reduction in cancer diagnosis compared to before the outbreak of COVID-19. In the UK, emergency referrals from primary care for people with suspected cancer reduced by 76%, and chemotherapy appointments for cancer patients decreased by 60% compared to the pre-COVID-19 levels. In France, the number of cancer diagnoses decreased by 35–50% in April 2020 compared to April 2019. As a result, disruptions in healthcare operations hampered the growth of the chemotherapy induced peripheral neuropathy market progress in 2020, due to the low number of chemotherapy sessions conducted during this period.
Various organic and inorganic strategies are adopted by companies in the chemotherapy-induced peripheral neuropathy market.The organic strategies mainly include product launches and product approvals.

Further, inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships.These growth strategies allow the chemotherapy-induced peripheral neuropathy market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth.

Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the chemotherapy-induced peripheral neuropathy market are listed below.
• In April 2021, WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study "Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults" was included in the special edition of the Toxins Journal, as was the study "Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX.”
• In December 2020, Regenacy announced a joint venture with 3E Bioventures for the development of ricolinostat in China, which will be followed by a US-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. BC Regenacy’s lead program will evaluate the efficacy and safety of ricolinostat in patients with chemotherapy-induced peripheral neuropathy in China.

A few of the major primary and secondary sources referred to while preparing the report on the chemotherapy-induced peripheral neuropathy market are the World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Neuromodulation Market by Type, Application - Global Forecast to 2027

  • $ 4950
  • August 2022
  • 207 pages

The global neuromodulation market is valued at an estimated USD 6.0 billion in 2022 and is projected to reach USD 10.4 billion by 2027, at a CAGR of 11.8% during the forecast period. Market growth is driven ...

  • World
  • North America
  • Neurological Disorder
  • Healthcare
  • Industry analysis
  • Drug Approval
  • Health Expenditure


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on